[2]Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IH...
[2] Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH...
目前,针对不同HER2表达水平乳腺癌的多种ADC已完成部分临床试验并投入临床应用(见表1)。 表1 已完成的针对不同HER2亚型乳腺癌的ADC临床试验 已完成的针对不同HER2状态乳腺癌的ADC临床试验 HER2阴性(IHC0)乳腺癌 CDX-011由靶向肿瘤特异性抗原糖蛋白NMB(gpNMB)的全人源单克隆抗体和强效微管抑制剂单甲基澳瑞他汀E(M...
[6]Hurvtiz A, Bardia A, Punie K, et al. Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cnacer (mTNBC) by HER2 immunohistochemistry (IHC) status: findings from the phase 3 ASCENT study. Presented at: European Society for Medical Oncology Breast Cancer...
HER2低表达被定义为IHC 1+或IHC 2+且满足FISH检测HER2无扩增。这些患者大多数为激素受体(HR)阳性(65%-83%)肿瘤。HER2低表达乳腺癌常见的一些临床病理学特征包括:肿瘤体积较大、组织病理学分级较高、增殖指数较高、腋窝淋巴结转移较多,这在临床上与HER2阳性患者相似[4]。此外,HR阳性/HER2低表达肿瘤的分子特征与...
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020 Feb 10;38(5):444-453. [3] Gianni L, Lladó A, Bianchi G, et al. ...
HER2低表达的免疫组化(IHC)水平是否可以预示T-DXd的疗效? 目前,HER2免疫组化评分(IHC)对传统HER2阴性乳腺癌的预测价值尚不明确。DB-04研究入组了321例IHC 1+和236例IHC 2+/ISH-的患者,亚组分析显示T-DXd组相比TPC组的HER2 IHC 1+(PFS:10.0 vs. 4.8个月,HR 0.48)和IHC 2+(PFS:9.9 vs. 5.1个月,HR...
这一发现为临床决策提供重要启示:对于高增殖活性(Ki-67≥50%)或3级HER2-zero肿瘤,卡铂强化方案可能带来更大获益。研究同时指出当前HER2分类系统的局限性——单纯依据IHC评分可能掩盖肿瘤生物学异质性,未来需结合基因组特征进一步细分治疗人群。 从转化医学角度看,该成果为优化TNBC新辅助治疗策略提供三级证据:1) 验证...
Trends were also found for the prolonged distant recurrence-free, disease-free, and overall survivals in the HER2-negative patients by IHC (2+). Trends for poor clinical response ( P =0.06) and more axillary nodes involvement ( P =0.08) were noted in the HER2-positive group by IHC (2+...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...